ARE

Alexandria highlights major NYC life science exits and launches a long-term depression study.

Alexandria posts a large loss on impairments but maintains strong liquidity and active capital recycling.

Alexandria secures $5.0 billion credit line with lower rates and extended maturity to 2032.

Earnings call scheduled; no financial results disclosed yet.

Alexandria priced $1 billion in new debt at a 7.25% interest rate.

Alexandria posts improved results, strong leasing, and robust liquidity despite a quarterly net loss.

Aecon posts strong revenue growth but remains unprofitable amid major capital commitments.

Aecon secured a stake in a major dam rehab, but financial impact remains undisclosed.

Alexandria touts a $70M research initiative, but offers little evidence of near-term impact.

This is a legal warning, not an investment signal—no actionable company data is disclosed.

Aecon’s big port project news is all promise, no numbers, and years from payoff.

This is a feel-good PR update with no direct investment relevance or financial substance.

ESG progress is real, but financial transparency is lacking—investors should stay cautious.

Aecon’s U.S. nuclear expansion is long on promise, short on hard financial facts.

Aecon’s $320M buyout is bold, but benefits are distant and mostly unproven.

This is just a routine earnings call notice—no actionable financial information is disclosed.

This is a feel-good PR move, not a material investment signal for ARE shareholders.

This is a self-congratulatory award announcement with little actionable financial substance.

Aecon landed a big Ontario LRT role, but financial impact remains unclear and distant.

Aecon’s backlog is at a record, but profits remain elusive and risks are rising.

Alexandria’s numbers are sliding, but management is betting on a near-term turnaround.